Number of the records: 1  

Targeting Keap1/Nrf2/ARE signaling pathway in multiple sclerosis

  1. 1.
    0537237 - MBÚ 2021 RIV NL eng J - Journal Article
    Michalčíková, D. - Hrnčíř, Tomáš - Kutinová Canová, N. - Slanař, O.
    Targeting Keap1/Nrf2/ARE signaling pathway in multiple sclerosis.
    European Journal of Pharmacology. Roč. 873, APR 15 (2020), č. článku 172973. ISSN 0014-2999. E-ISSN 1879-0712
    R&D Projects: GA ČR(CZ) GA20-09732S
    Institutional support: RVO:61388971
    Keywords : Nrf2 inducers * Curcumin * Melatonin * Resveratrol * EGCG * Flavonoids
    OECD category: Neurosciences (including psychophysiology
    Impact factor: 4.432, year: 2020
    Method of publishing: Limited access
    https://www.sciencedirect.com/science/article/pii/S0014299920300650

    Multiple sclerosis (MS) is a neurologic autoimmune disorder featured by chronic inflammation of the central nervous system, demyelination and axonal damage. Recently, the term ´oxinflammation´ has been proposed to depict the vicious circle of chronic inflammation and oxidative stress (OS). OS promotes demyelination and neurodegeneration directly, by oxidation of lipids, proteins, and DNA but also indirectly, by inducing a dysregulation of the immunity and favoring the state of pro-inflammatory response. Many of the actors of this delicately tuned network are controlled by Keap1/Nrf2/ARE signaling pathway, a principal regulator of antioxidant and phase II detoxification genes. This pathway also has a pivotal role in inflammation, and therefore possesses a great potential in the treatment of MS. The aim of this review is to provide the newest insights in the preclinical and clinical evidence of Nrf2 induction in the regeneration of the antioxidant response and attenuation of inflammation in MS. Preclinical studies have indicated that activators of this pathway, such as epigallocatechin gallate (EGCG), curcumin, melatonin, resveratrol, and sulforaphane might be a promising therapeutic option in amelioration of MS symptoms, nevertheless, the efficacy and safety of these compounds have to be confirmed in future clinical trials.
    Permanent Link: http://hdl.handle.net/11104/0314973

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.